Hemosol B0

Hemosol B0 is an injectable electrolyte solution containing calcium, lactic acid, magnesium, sodium, chloride ion, and hydrogen carbonate. It is supplied as a sterile solution for injection, intended for use in haemodialysis and intravenous fluid and electrolyte replacement. The product conforms to European Union standards and is prescribed by healthcare professionals for patients requiring controlled electrolyte balance during renal replacement therapy as part of clinical management.

Hemosol B0 is indicated for specific clinical situations where precise electrolyte control is required.

- Replacement of electrolytes during haemodialysis procedures. - Intravenous fluid therapy for patients with acute or chronic electrolyte disturbances. - Support of acid‑base balance in patients receiving large-volume resuscitation. - Adjunctive use in peri‑operative settings where rapid electrolyte correction is needed. - Management of hypocalcemia or hypomagnesemia in conjunction with other prescribed therapies. - Provision of a balanced electrolyte composition for patients undergoing continuous renal replacement therapy (CRRT).

The safety profile of Hemosol B0 reflects the electrolyte composition of the solution; adverse events are generally related to the infusion process or electrolyte shifts.

Common: - Mild transient nausea or vomiting. - Localized infusion site discomfort or erythema. - Temporary headache. - Mild hypotension during rapid administration.

Serious: - Severe hypercalcemia or hypermagnesemia. - Cardiac arrhythmias associated with electrolyte imbalance. - Pulmonary edema from fluid overload. - Anaphylactic or severe hypersensitivity reactions.

When prescribing Hemosol B0, clinicians should evaluate patient-specific factors and monitor relevant parameters to minimize risks.

- Assess baseline serum electrolytes, especially calcium, magnesium, and sodium, before initiation. - Adjust infusion rate in patients with compromised cardiac function or fluid overload risk. - Use caution in pregnant or lactating women; safety data are limited. - Monitor acid‑base status regularly during prolonged therapy. - Avoid concurrent administration with other high‑concentration electrolyte solutions without appropriate adjustments. - Consider renal function; dose modifications may be required in severe impairment. - Document any allergic reactions to solution components.

Hemosol B0 may interact with other medications that influence electrolyte balance or fluid status.

Avoid: - Concurrent infusion of calcium‑containing medications without dose adjustment. - High‑dose magnesium supplements or antacids that could precipitate hypermagnesemia. - Sodium bicarbonate solutions administered simultaneously, which may cause abrupt pH shifts.

Use with caution: - Loop diuretics, which can exacerbate electrolyte losses. - ACE inhibitors or ARBs, which may affect potassium and sodium homeostasis. - Blood products containing potassium, requiring careful monitoring. - Vasopressors, as rapid fluid shifts can influence hemodynamic response.